Drug Safety Bulletin Being Considered By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The effort would be overseen by new Associate Center Director for Safety Policy & Communication Paul Seligman.
You may also be interested in...
CDER Abandons “Drug Watch” Program To Communicate Safety In Favor Of Asterisk
FDA issues final guidance describing its approach to communicating drug safety information, including emerging information, to the public.
CDER Abandons “Drug Watch” Program To Communicate Safety In Favor Of Asterisk
FDA issues final guidance describing its approach to communicating drug safety information, including emerging information, to the public.
FDA Doesn’t Need New “Hammers” For Drug Safety, Gottlieb Says
Deputy commissioner says that improving technology, not revamping the agency’s oversight authority, will lead to post-marketing improvements.